XTNT PE Ratio & Valuation,Is XTNT Overvalued

XTNT Relative Valuation

XTNT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, XTNT is overvalued; if below, it's undervalued.

Historical Valuation

Xtant Medical Holdings Inc (XTNT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.88 is considered Fairly compared with the five-year average of -12.93. The fair price of Xtant Medical Holdings Inc (XTNT) is between 0.52 to 1.43 according to relative valuation methord.

Relative Value

Fair Zone

0.52-1.43

Current Price：0.72

Fair

-144.20

12.12

EV/EBITDA

Xtant Medical Holdings Inc. (XTNT) has a current EV/EBITDA of 12.12. The 5-year average EV/EBITDA is 21.27. The thresholds are as follows: Strongly Undervalued below -19.37, Undervalued between -19.37 and 0.95, Fairly Valued between 41.59 and 0.95, Overvalued between 41.59 and 61.91, and Strongly Overvalued above 61.91. The current Forward EV/EBITDA of 12.12 falls within the Historic Trend Line -Fairly Valued range.

70.62

EV/EBIT

Xtant Medical Holdings Inc. (XTNT) has a current EV/EBIT of 70.62. The 5-year average EV/EBIT is -6.49. The thresholds are as follows: Strongly Undervalued below -114.27, Undervalued between -114.27 and -60.38, Fairly Valued between 47.40 and -60.38, Overvalued between 47.40 and 101.28, and Strongly Overvalued above 101.28. The current Forward EV/EBIT of 70.62 falls within the Overvalued range.

0.88

Xtant Medical Holdings Inc. (XTNT) has a current PS of 0.88. The 5-year average PS is 1.03. The thresholds are as follows: Strongly Undervalued below -0.37, Undervalued between -0.37 and 0.33, Fairly Valued between 1.73 and 0.33, Overvalued between 1.73 and 2.43, and Strongly Overvalued above 2.43. The current Forward PS of 0.88 falls within the Historic Trend Line -Fairly Valued range.

56.39

P/OCF

Xtant Medical Holdings Inc. (XTNT) has a current P/OCF of 56.39. The 5-year average P/OCF is 34.96. The thresholds are as follows: Strongly Undervalued below -206.24, Undervalued between -206.24 and -85.64, Fairly Valued between 155.55 and -85.64, Overvalued between 155.55 and 276.15, and Strongly Overvalued above 276.15. The current Forward P/OCF of 56.39 falls within the Historic Trend Line -Fairly Valued range.

-1015.03

P/FCF

Xtant Medical Holdings Inc. (XTNT) has a current P/FCF of -1015.03. The 5-year average P/FCF is -33.41. The thresholds are as follows: Strongly Undervalued below -373.03, Undervalued between -373.03 and -203.22, Fairly Valued between 136.41 and -203.22, Overvalued between 136.41 and 306.22, and Strongly Overvalued above 306.22. The current Forward P/FCF of -1015.03 falls within the Strongly Undervalued range.

Xtant Medical Holdings Inc (XTNT) has a current Price-to-Book (P/B) ratio of 2.00. Compared to its 3-year average P/B ratio of 2.23 , the current P/B ratio is approximately -10.20% higher. Relative to its 5-year average P/B ratio of 2.77, the current P/B ratio is about -27.74% higher. Xtant Medical Holdings Inc (XTNT) has a Forward Free Cash Flow (FCF) yield of approximately 5.10%. Compared to its 3-year average FCF yield of -11.82%, the current FCF yield is approximately -143.09% lower. Relative to its 5-year average FCF yield of -8.18% , the current FCF yield is about -162.28% lower.

2.00

P/B

Median3y

2.23

Median5y

2.77

5.10

FCF Yield

Median3y

-11.82

Median5y

-8.18

Competitors Valuation Multiple

The average P/S ratio for XTNT's competitors is 1.63, providing a benchmark for relative valuation. Xtant Medical Holdings Inc Corp (XTNT) exhibits a P/S ratio of 0.88, which is -45.95% above the industry average. Given its robust revenue growth of 19.04%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of XTNT increased by 63.66% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 24.20 to 64.49.

The secondary factor is the Revenue Growth, contributed 19.04%to the performance.

Overall, the performance of XTNT in the past 1 year is driven by P/E Change. Which is more unsustainable.

19.04%

27.94M → 33.26M

Revenue Growth

-121.86%

-17.98 → 3.93

Margin Expansion

166.48%

24.20 → 64.49

P/E Change

63.66%

0.44 → 0.73

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Xtant Medical Holdings Inc (XTNT) currently overvalued or undervalued?

What is Xtant Medical Holdings Inc (XTNT) fair value?

XTNT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Xtant Medical Holdings Inc (XTNT) is between 0.52 to 1.43 according to relative valuation methord.

How does XTNT's valuation metrics compare to the industry average?

What is the current P/B ratio for Xtant Medical Holdings Inc (XTNT) as of Dec 15 2025?

As of Dec 15 2025, Xtant Medical Holdings Inc (XTNT) has a P/B ratio of 2.00. This indicates that the market values XTNT at 2.00 times its book value.

What is the current FCF Yield for Xtant Medical Holdings Inc (XTNT) as of Dec 15 2025?

As of Dec 15 2025, Xtant Medical Holdings Inc (XTNT) has a FCF Yield of 5.10%. This means that for every dollar of Xtant Medical Holdings Inc’s market capitalization, the company generates 5.10 cents in free cash flow.

What is the current Forward P/E ratio for Xtant Medical Holdings Inc (XTNT) as of Dec 15 2025?

As of Dec 15 2025, Xtant Medical Holdings Inc (XTNT) has a Forward P/E ratio of -144.20. This means the market is willing to pay $-144.20 for every dollar of Xtant Medical Holdings Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Xtant Medical Holdings Inc (XTNT) as of Dec 15 2025?

As of Dec 15 2025, Xtant Medical Holdings Inc (XTNT) has a Forward P/S ratio of 0.88. This means the market is valuing XTNT at $0.88 for every dollar of expected revenue over the next 12 months.

XTNT Valuation